1. Introduction {#s0005}
===============

Sepsis, a microbial induced inflammatory response, encompasses a spectrum of illness that ranges from systemic infection to multiple organ dysfunction syndrome (MODS) [@bb0005]. Mortality due to septic cardiac dysfunction has been encountered in critically ill patients [@bb0010] where an increased heart rate may act as an independent risk factor [@bb0015]. Patients with lower heart rate in the early phase of MODS have better survival rates than those with higher heart rate [@bb0015].

Sepsis is induced by lipopolysaccharide (LPS, endotoxin), a major component of the outer cell wall of gram-negative bacteria. Notably, LPS from wild type bacteria usually is a mix of S-form LPS and varying proportions of so-called R-form LPS [@bb0020]. S-form LPS consists of three entities: the lipid A moiety, that harbours the endotoxic activity of the entire molecule, the core oligosaccharide and the O-polysaccharide chain, that is absent in R-form LPS [@bb0025; @bb0030]. Irrespective of their structural components, both LPS forms are capable to initiate sepsis by triggering the inflammatory response [@bb0035]. Besides initiating the inflammatory response, S-form LPS directly affects ionic channels of immune, neuronal and cardiovascular cells [@bb0040; @bb0045; @bb0050], the latter include channels conducting the pacemaker current *I*~f~. This current is a mixed Na^+^/K^+^ inward current carried by pacemaker channels comprising four different homo- or heteromeric isoforms of hyperpolarization-activated cyclic nucleotide-gated (HCN 1--4) channels [@bb0055]. *I*~f~ plays an important role in the regulation of heart rate [@bb0060] by contributing to the slow diastolic depolarization phase that determines the firing rate of spontaneous action potentials of sinoatrial node cells [@bb0065]. Moreover, in response to autonomic transmitters, *I*~f~ contributes to the chronotropic regulation of heart rate [@bb0065]. Previously, we reported *I*~f~ loss-of-function in human atrial myocytes after chronic S-LPS treatment, an observation that in turn might be responsible for reduction of heart rate variability during sepsis [@bb0070; @bb0075]. Meanwhile it was shown that S-form LPS also acutely impairs *I*~f~ [@bb0080; @bb0085] and that the polysaccharide part (O-chain) of the LPS molecule [@bb0080] is necessary for reduction of pacemaker channel activity.

Beta-blocker administration has been shown to reduce mortality in MODS [@bb0090; @bb0095]. However, negative inotropic effects of beta-blockers restrict its use in the majority of patients. Therefore, ivabradine may be considered as an alternative therapeutic approach to reduce heart rate. This drug is a pure heart rate lowering agent that selectively inhibits *I*~f~ [@bb0100]. Ivabradine blocks pacemaker channels in a use-dependent way being more effective at higher heart rate while its action declines during bradycardia [@bb0105; @bb0110]. Blocking of pacemaker channels by ivabradine requires three steps: diffusion through the cell membrane, opening of respective channels and intracellular binding of the drug to the channel pore [@bb0100; @bb0115]. Heart rate reduction by ivabradine has been found to be beneficial in the treatment of cardiovascular disease, since it lowers heart rate without adversely affecting other cardiovascular functions [@bb0120].

Currently, the MOD*I*~f~Y trial carefully investigates potential benefits of heart rate reduction by ivabradine in sepsis and MODS [@bb0095]. Since S-LPS substantially inhibits *I*~f~ and ivabradine is administered in septic patients (MOD*I*~f~Y trial), we hypothesized that *I*~f~ reduction by S-LPS might interfere with ivabradine action on *I*~f~. From a clinical perspective, the efficacy of *I*~f~ inhibition by ivabradine under septic conditions is of special therapeutic relevance.

In this study we investigated the effect of S-LPS and R595 on human atrial *I*~f~ under acute and chronic septic conditions as well as the interaction of both endotoxins with HCN channels. Next, we focused on the effect of endotoxins on (i) *I*~f~ reduction by ivabradine and (ii) intracellular ivabradine concentrations. Finally, using a computer simulation model we tried to explore the efficacy of ivabradine on deceleration of sinoatrial pacemaking activity under septic conditions.

2. Material and methods {#s0010}
=======================

A detailed Materials and methods section on isolation of cardiomyocytes [@bb0125; @bb0130; @bb0135], cell culture [@bb0140], myocyte treatments, patch-clamp measurements [@bb0070; @bb0145; @bb0150], immunoprecipitation [@bb0155], Western blot and immuno-dot-blot [@bb0160], qPCR [@bb0165], determination of ivabradine concentrations by HPLC [@bb0170] and sinoatrial pacemaker cell modeling [@bb0175] is available under the online supplemental section.

3. Results {#s0075}
==========

3.1. Representative recordings of *I*~f~ of human atrial myocytes {#s0015}
-----------------------------------------------------------------

[Fig. 1](#f0005){ref-type="fig"} shows representative traces of *I*~f~ under control ([Fig. 1](#f0005){ref-type="fig"}A), ivabradine ([Fig. 1](#f0005){ref-type="fig"}B) and septic conditions (mimicked *in vitro* by LPS incubation, [Figs. 1](#f0005){ref-type="fig"}C and D) elicited by hyperpolarizing voltage steps from − 40 to − 130 mV. *I*~f~ was considered to be present when current density was higher than 0.5 pA/pF at − 120 mV; this was the case in about 90% of all tested human atrial myocytes. The prominent reduction of *I*~f~ by ivabradine ([Fig. 1](#f0005){ref-type="fig"}B) reveals the heart rate lowering potency of this drug [@bb0180]. Under septic conditions only S-LPS ([Fig. 1](#f0005){ref-type="fig"}C) but not R595 ([Fig. 1](#f0005){ref-type="fig"}D) caused a more negative *I*~f~ activation threshold (control: between − 60 and − 70 mV, S-LPS: between − 70 and − 80 mV; note the arrows indicating current at − 70 mV). Irrespective of their origin, both S-LPS preparations (extracted from either *Escherichia coli* or *Salmonella enterica* serotype *Minnesota*) had an almost identical effect on *I*~f~ steady-state activation (Supplemental Fig. S1).

3.2. Effect of endotoxins on *I*~f~ of human atrial myocytes {#s0020}
------------------------------------------------------------

In order to investigate *I*~f~ under acute application of endotoxins, cells were superfused (6 min) with either S-LPS or R595. [Fig. 2](#f0010){ref-type="fig"}A shows representative pacemaker current recordings at indicated membrane potentials before and after S-LPS superfusion. S-LPS treatment resulted in a significant (i) reduction of *I*~f~ between − 60 and − 130 mV ([Fig. 2](#f0010){ref-type="fig"}B), (ii) shift of steady-state activation of *I*~f~ towards more negative membrane potentials ([Fig. 2](#f0010){ref-type="fig"}C) and (iii) slowing down of *I*~f~ current activation ([Fig. 2](#f0010){ref-type="fig"}D). The maximal *I*~f~ reduction by S-LPS occurred between 3 and 4 min ([Fig. 2](#f0010){ref-type="fig"}E) and was significantly more pronounced than the time-dependent *I*~f~ rundown (see also Supplemental Fig. S2). In line with a recent study where R595 had no acute effects on HCN2 current [@bb0080], we also did not observe any R595-mediated acute effects on *I*~f~ in human cardiomyocytes (data not shown).

In order to investigate *I*~f~ under chronic conditions, myocytes were incubated with endotoxins for 6--10 h. In line with our previous findings [@bb0070] S-LPS shifted *I*~f~ steady-state activation towards more negative membrane potentials, slowed down its current activation (data not shown) and significantly reduced current density at − 70 and − 80 mV. In contrast to S-LPS, R595 did neither reduce *I*~f~ ([Fig. 3](#f0015){ref-type="fig"}A) nor alter *I*~f~ steady-state activation or time constants of *I*~f~ activation compared to controls ([Figs. 3](#f0015){ref-type="fig"}B and C).

3.3. Interactions of endotoxins with HCN channels {#s0025}
-------------------------------------------------

Acute S-LPS perfusion rapidly decreased *I*~f~ in human cardiomyocytes ([Fig. 2](#f0010){ref-type="fig"}E). Furthermore, S-LPS superfusion of HEK293 cells overexpressing HCN2 (the major isoform expressed in human atrial myocytes [@bb0185]) was found to reduce *I*~f~ by approx. 30% within 8 s [@bb0080]. These observations suggest a direct interaction of S-LPS with HCN channels. In order to test this hypothesis, a series of dot-blot experiments was performed. S-LPS and R595 preparations were cross-linked to activated (prewetted) PVDF membranes. After drying (inactivation) the membranes were incubated with either HCN2 or HCN4 (the major isoform in sinoatrial node cells [@bb0190]) that had been immunoprecipitated from murine heart (Supplemental Fig. S3). Using specific antibodies to follow endotoxin--HCN interactions, immunoreactive signals for HCN2 ([Fig. 4](#f0020){ref-type="fig"}A \[2a, 3a\]) and HCN4 (Supplemental Fig. S4) could only be detected with S-LPS (but not R595) cross-linked membranes. Observations that S-LPS and R595 interact with HDL/apoA-I (the major apolipoprotein of HDL, [Fig. 4](#f0020){ref-type="fig"}A \[4a\]), a known ligand for both LPS preparations [@bb0195], confirm the capacity of both endotoxin preparations to interact with candidate ligands. To further validate our findings, endotoxin-cross-linked membranes were incubated with murine total IgG, being present in immunoprecipitated HCN2; the lack of immunoreactivity ([Fig. 4](#f0020){ref-type="fig"}A \[5a\]) confirmed that the observed S-LPS--HCN2 interaction is specific and not due to S-LPS--IgG interaction. In addition, no immunoreactive signals were observed when inactivated membranes were incubated with either HCN2 or HDL ([Fig. 4](#f0020){ref-type="fig"}A \[2b, 3b, 4b\]), while incubation of HCN2 or HDL to activated membranes showed immunoreactivity ([Fig. 4](#f0020){ref-type="fig"}A \[3c, 4c\]). These negative and positive controls further confirm the specificity of S-LPS--HCN channel interaction.

As immunoprecipitated HCN2 and HCN4 were denatured by LDS sample buffer, the unspecific interaction of S-LPS with unfolded channel might have occurred. To show that also non-denatured HCN2 and HCN4 channels interact with endotoxins, cross-linked membranes were incubated with murine heart protein lysates; these experiments confirm interaction of intact HCN2 and HCN4 channels to S-LPS but not R595 (data not shown).

*I*~f~ is impaired in a similar manner under acute ([Fig. 2](#f0010){ref-type="fig"}B) and chronic S-LPS conditions ([Fig. 3](#f0015){ref-type="fig"}A) and S-LPS interacts with both HCN channel isoforms ([Fig. 4](#f0020){ref-type="fig"}A, Supplemental Fig. S4). To gain insights whether chronic endotoxin treatment could modulate channel expression, HL-1 cells (where *I*~f~ reduction after S-LPS treatment was previously reported [@bb0200]) were used. Both endotoxins did not alter mRNA (HCN2 and HCN4, up to 24 h) or protein expression (HCN2, 6 and 24 h); only the 6 h time point is shown ([Fig. 4](#f0020){ref-type="fig"}B, a/b).

3.4. Effect of ivabradine on *I*~f~ of human atrial myocytes {#s0030}
------------------------------------------------------------

[Fig. 5](#f0025){ref-type="fig"}A shows the effect of ivabradine on *I*~f~ elicited by *protocol 1 (p1,* see inset) before and after ivabradine superfusion of cardiomyocytes. A use-dependent *I*~f~ block by ivabradine was established by *protocol 2* (*p2*, see inset). Ivabradine significantly reduced *I*~f~ (from − 80 to − 130 mV) but did not change steady-state ([Fig. 5](#f0025){ref-type="fig"}B) or time constants of *I*~f~ activation ([Fig. 5](#f0025){ref-type="fig"}C). A current rundown was observed after stimulation of control cardiomyocytes using *protocol p2*. Ivabradine-induced *I*~f~ reduction (dark grey bars) was significantly higher compared to current rundown in controls (white bars) at all given membrane potentials ([Fig. 6](#f0030){ref-type="fig"}D).

3.5. Effect of ivabradine on *I*~f~ of human atrial myocytes under septic conditions {#s0035}
------------------------------------------------------------------------------------

Ivabradine treatment significantly reduced *I*~f~ at membrane potentials from − 90 to − 130 mV in both S-LPS- and R595-incubated cardiomyocytes ([Figs. 6](#f0030){ref-type="fig"}A and B). The significantly reduced *I*~f~ current density at a membrane potential of − 80 mV in R595 incubated cells ([Fig. 6](#f0030){ref-type="fig"}B) did not differ from current rundown ([Fig. 6](#f0030){ref-type="fig"}D).

[Fig. 6](#f0030){ref-type="fig"}C shows the time-dependent development of ivabradine induced *I*~f~ blockage in control and S-LPS/R595 incubated cells at a membrane potential of − 100 mV (*protocol p2*, see inset [Fig. 5](#f0025){ref-type="fig"}A). In order to calculate *I*~f~ reduction five consecutive measurements of current densities during a 30 s period were averaged and normalized to initial values. *I*~f~ blockage by ivabradine was significantly higher in controls than in endotoxin incubated cells but did not differ between the two LPS forms. Furthermore, current rundown in control cardiomyocytes (beginning 2.5 min after *protocol p2* had been started) was significantly smaller than *I*~f~ reduction in all ivabradine-treated cardiomyocytes. [Fig. 6](#f0030){ref-type="fig"}D shows that the efficacy of ivabradine to block *I*~f~ is significantly reduced in endotoxin incubated myocytes over a wide membrane potential range. *I*~f~ reduction was calculated from the underlying *I--V* relationships before and after ivabradine superfusion.

*I*~f~ steady-state activation (which is shifted towards more negative membrane potentials by S-LPS but not R595) was not further affected by ivabradine in endotoxin-treated myocytes (data not shown).

3.6. Effect of endotoxins on intracellular ivabradine concentrations in guinea pig ventricular myocytes {#s0040}
-------------------------------------------------------------------------------------------------------

Under septic conditions *I*~f~ inhibition by ivabradine is reduced compared to controls ([Figs. 6](#f0030){ref-type="fig"}C and D). Since ivabradine diffuses across the cell membrane [@bb0115] and S-LPS is known to change cell membrane integrity [@bb0205], a reduction in intracellular ivabradine concentrations in endotoxin incubated myocytes might be the consequence. To test this hypothesis, intracellular ivabradine concentrations were measured in guinea pig cardiomyocytes due to the limited yield of human myocytes. Representative HPLC-chromatograms are shown in [Fig. 7](#f0035){ref-type="fig"}A. Intracellular ivabradine concentrations ranged between 1.55 and 3.31 pmoL/mg total cell protein in different control myocyte preparations. From [Fig. 7](#f0035){ref-type="fig"}B, it is evident that incubation of cells with S-LPS (but not R595) significantly reduced intracellular ivabradine concentrations compared to respective controls.

3.7. Effect of ivabradine on sinoatrial pacemaking activity in the presence of S-LPS: a computer simulation model {#s0045}
-----------------------------------------------------------------------------------------------------------------

To gain first indications whether an impaired *I*~f~ (by S-LPS) is still a suitable target for ivabradine to reduce sinoatrial beating rate, experimental data were implemented in a sinoatrial computer cell model [@bb0175]. Based on our present and previously reported [@bb0070] experimental data using human myocytes, the effect of S-LPS was implemented in the model as an *I*~f~ *V*~1/2~ shift of − 14 mV (which represents a shift of *I*~f~ *V*~1/2~ in the sinoatrial cell model from − 52.5 to − 66.5 mV). The action of ivabradine was simulated by reduction of *I*~f~ conductance (66% and 35% in control and S-LPS incubated cells, respectively; see [Figs. 5](#f0025){ref-type="fig"}A and [6](#f0030){ref-type="fig"}A).

In this simulation model, ivabradine (open squares) reduced *I*~f~ at all membrane potentials, while S-LPS (filled circles) had a reducing effect on *I*~f~ between − 50 and − 100 mV ([Fig. 8](#f0040){ref-type="fig"}A). At membrane potentials positive to approximately − 65 mV, *I*~f~ reduction by S-LPS was more pronounced compared to ivabradine. Combining effects of both compounds, the most prominent decrease of *I*~f~ between − 40 and − 70 mV became apparent (grey diamonds). The gradual decrease of *I*~f~ at physiologically relevant membrane potentials ([Fig. 8](#f0040){ref-type="fig"}A) resulted in a gradual increase in cycle length (CL) from 355 ms (controls (1)) to 455 ms (ivabradine (2)), 569 ms (S-LPS (3)) and 604 ms (S-LPS and ivabradine (4), [Fig. 8](#f0040){ref-type="fig"}B). A systematic variation of the two *I*~f~ model parameters ([Fig. 8](#f0040){ref-type="fig"}C) predicts that CL is more strongly influenced by an *I*~f~ *V*~1/2~ shift (to more negative membrane potentials) than by reduction of *I*~f~ conductance. For example, CL alteration by an *I*~f~ *V*~1/2~ shift of only − 2 mV is equivalent to a 20% decrease in *I*~f~ conductance. Moreover, the simulation model clearly shows that at all given *V*~1/2~ values (shifted by S-LPS), a reduction of *I*~f~ conductance due to ivabradine treatment leads to an additional decrease in CL. In conclusion, ivabradine is efficient to decelerate sinoatrial pacemaking activity *in silico* in the presence of S-LPS.

4. Discussion {#s0050}
=============

Sepsis and sepsis induced MODS are considered as highly complex diseases where heart pacemaking function is expected to be modulated by direct and indirect endotoxin effects [@bb0075; @bb0210]. In the present study, we exclusively focused on the direct effects of endotoxin on human atrial pacemaker current (*I*~f~). We here report that S-LPS exerts besides a chronic also an acute inhibitory effect on human *I*~f~. Our data provide an explanation for S-LPS-induced impairment of *I*~f~, namely the interaction of the O-chain of S-LPS to the HCN channel. Furthermore, we explored the effect of ivabradine on *I*~f~ under septic conditions. To our knowledge, we are the first to show that the inhibitory action of ivabradine on *I*~f~ is reduced under elevated endotoxin concentrations. However, our *in silico* results show that the efficacy of ivabradine to decelerate pacemaking activity is preserved under septic conditions.

Previously we have reported *I*~f~ impairment in human myocytes under chronic S-LPS conditions [@bb0070]. We now report reduction of *I*~f~ by S-LPS (but not R595) under acute conditions. The data are in line with findings obtained in other cellular models (HEK293 cells overexpressing HCN2 or HL-1 cells [@bb0080; @bb0085]). In addition, our data reveal direct interactions between S-LPS (but not R595) and cardiac HCN channels, namely HCN2 (the predominant isoform in human atrial myocytes [@bb0185]) and HCN4 (the prevalent isoform in sinoatrial node cells [@bb0190]). However, the exact binding site(s) of S-LPS to the respective HCN channels remain to be explored.

HCN4 is considered as the main isoform contributing to the sinoatrial pacemaking process [@bb0065]. Thus, binding of S-LPS to HCN4 most likely accounts for *I*~f~ impairment in murine sinoatrial node cells [@bb0080] and may contribute to reduction of beating rate in spontaneously active murine HL-1 cells [@bb0085].

Pacemaker channels may also be indirectly affected by inflammatory cytokines (e.g. TNFα) released in response to bacterial and viral infections. Cytokines have been reported to play a pivotal role in gram-negative sepsis, particularly in myocardial dysfunction [@bb0215; @bb0220], probably by causing alterations in calcium homeostasis and production of nitric oxide (NO). The latter has been shown to modulate a number of cardiac ionic currents [@bb0225; @bb0230] including the sinoatrial pacemaker current [@bb0235] which can be stimulated by NO. This stimulation may partly contribute to sinus tachycardia in septic shock. Similar cascades are evoked by gram-positive sepsis which also may modulate pacemaker channel activity and hence heart rate [@bb0240; @bb0245]. Furthermore, inflammatory cytokines (interferons) released in response to viral brain infections have been reported to inhibit neuronal pacemaker channel activity [@bb0250]. Taken together, cytokine-dependent modulations of pacemaker channels provide a further cellular mechanism to alter sinoatrial pacemaking as well as neuronal network oscillations.

Ivabradine blocks *I*~f~ in cardiomyocytes including both human atrial [@bb0185] and rabbit sinoatrial node cells [@bb0100] as well as HCN4 overexpressing CHO cells [@bb0255]. We also observed *I*~f~ reduction (approx. 66%) by 1 μmol/L ivabradine (at membrane potentials from − 80 to − 130 mV), a concentration which has no effects on other membrane currents [@bb0100; @bb0260].

Under septic conditions, *I*~f~ block by ivabradine is significantly attenuated. *I*~f~ blocking capacity in the presence of S-LPS is paralleled by reduced intracellular ivabradine concentrations. As a consequence, less ivabradine is likely to be available for binding to the inner channel pore. Moreover, an altered access and/or binding behaviour of ivabradine due to S-LPS--HCN interaction might further influence ivabradine\'s blocking potency. None of these mechanisms are likely to occur for R595 treatment since this LPS-form did not alter intracellular ivabradine concentration or interact with the HCN channels. The exact mechanism how R595 modulates action of ivabradine on *I*~f~ remains to be further investigated. It is worth mentioning that the susceptibility of gram-negative bacteria towards hydrophobic agents also depends on the LPS-form on their surface [@bb0265]. For example, in case of deep-rough Re-LPS mutant strains, hydrophobic antibiotics such as macrolides readily access the cell surface and permeate into the cell interior through the lipid bilayer, while no accumulation was observed in strains having S-LPS [@bb0270]. Therefore, one may speculate that incorporation of S-LPS in human myocytes hinders the accumulation and transfer of the hydrophobic ivabradine.

Our data show that in the presence of S-LPS, *I*~f~ current densities are reduced at physiologically relevant membrane potentials. Therefore, the question arises whether a decreased *I*~f~ as found under septic conditions is still a suitable target for ivabradine in order to reduce sinoatrial beating rate. It is known that during the diastolic depolarization phase of the sinoatrial action potential, very small net inward currents are sufficient to depolarize the cell membrane towards the action potential threshold [@bb0275]. Since *I*~f~ of mammalian sinoatrial [@bb0080] and human atrial myocytes is impaired by S-LPS in a similar manner and the inhibitory effect of ivabradine on human atrial *I*~f~ is comparable to that on sinoatrial mammalian *I*~f~ [@bb0185], we implemented our experimental data into a sinoatrial cell model. This *in silico* approach suggests that ivabradine should still be capable of decreasing sinoatrial beating rate under septic conditions through *I*~f~ inhibition. Nevertheless, it has to be mentioned that sinoatrial pacemaking *in vivo* is a very complex process due to the close interaction of the membrane clock (cyclic opening and closing of membrane ion channels) and the calcium clock (rhythmic spontaneous Ca^2 +^ release from the sarcoplasmatic reticulum) [@bb0280]. Furthermore, the data presented in this study are gained from quiescent atrial myocytes, which exhibit differences in ion channel expression and hence electrophysiological characteristics. These differences might influence experimental outcome. Therefore further investigations using spontaneously active cardiomyocytes are required to confirm our conclusions and to get a deeper insight in the effect of ivabradine on heart rate under septic conditions *in vivo*. Such studies are of special interest since currently the clinical MOD*I~f~*Y trial studies the benefits of heart rate reduction by ivabradine in patients suffering from MODS [@bb0095], where heart rate is usually elevated due to increased oxygen demand and cytokine levels [@bb0285] and has been proved to predict survival [@bb0015; @bb0290]. Pure heart rate reduction by ivabradine could therefore improve the outcome of patients in shock by lowering myocardial oxygen demand, improving diastolic coronary perfusion and acting on the negative force-frequency relationship of the failing heart [@bb0285].

In summary, our data demonstrate for the first time that O-chain-dependent interaction of endotoxin to HCN channels mediates *I*~f~ reduction under septic conditions. Even though *I*~f~ blocking capacity of ivabradine is reduced under elevated endotoxin levels *in vitro*, this drug is effective to decelerate sinoatrial beating rate in the presence of S-LPS *in silico*. Thus, the medical application of ivabradine as a heart rate reducing agent in critically ill patients (during MODS and sepsis) might favor a better therapeutic outcome.
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![Representative pacemaker current recordings of human atrial myocytes.\
Pacemaker currents (pA) were recorded by hyperpolarizing voltage steps ranging from − 40 to − 130 mV (10 mV increment, holding potential − 40 mV, 3 s duration) and normalized to cell capacitance (pF) for a control cell (A) and for cells treated with indicated concentrations of ivabradine (7 min) (B), S-LPS (6 h) (C) or R595 (6 h) (D). Arrows indicate current at − 70 mV.](gr1){#f0005}

![Acute effects of S-LPS on pacemaker current of human atrial myocytes.\
(A) Representative superimposed current recordings of a cell before and after S-LPS superfusion (10 μg/mL, 6 min). (B) *I--V* relationships of *I*~f~ before and after S-LPS superfusion. (C) *I*~f~ steady-state activation before and after S-LPS superfusion. Normalized conductances were fitted by a Boltzmann function. Control: *V*~1/2~ = − 85.4 ± 3.0 mV, *k* = 8.8 ± 0.8 mV; LPS: *V*~1/2~ = − 98.0 ± 3.1 mV, *k* = 6.3 ± 0.4 mV. (D) Mean time constants of *I*~f~ activation before and after S-LPS superfusion. Values were obtained by fitting a monoexponential function to current traces. (E) Time-dependent current reduction of *I*~f~ by S-LPS and under control conditions. Repetitive voltage steps were applied to − 80 mV for 3 s from a holding potential of − 40 mV (1/30 Hz, 8 min). Measurements were normalized to initial values and reduction of current densities was calculated. \**p* ≤ 0.05 vs. control.](gr2){#f0010}

![Chronic effects of S-LPS and R595 on pacemaker current of human atrial myocytes.\
Cells were incubated with S-LPS or R595 (10 μg/mL, 6--10 h. (A) Mean *I--V* relationships of *I*~f~ in control and endotoxin-treated cells. (B) *I*~f~ steady-state activation for control and R595-treated cells. Normalized conductances were fitted by a Boltzmann function. Control: *V*~1/2~ = − 83.3 ± 1.2 mV, *k* = 7.8 ± 0.4 mV; R595: *V*~1/2~ = − 80.3 ± 1.3 mV, *k* = 7.0 ± 0.5 mV. (C) Mean time constants of *I*~f~ activation for control and R595-treated cells. Values were obtained by fitting a monoexponential function to current traces. ^+^*p* ≤ 0.05 vs. control and R595; ^§^*p* ≤ 0.05 vs. R595.](gr3){#f0015}

![LPS--HCN interactions.\
(A) Dot-blot analysis for LPS--HCN2 binding. a: S-LPS and R595 (10 μg) were cross-linked with methanol prewetted PVDF membranes. Membranes were dried and dots were incubated with PBS (1a), indicated volumes of immunoprecipitated HCN2 protein (2a/3a), HDL (4a) or purified murine total IgG (5a). b: Prewetted PVDF membranes were dried followed by dotting with immunoprecipitated HCN2 protein (2b/3b) or HDL (4b). c: Immunoprecipitated HCN2 protein (3c) or HDL (4c) was dotted onto prewetted membranes. After all incubation steps lanes 1--5 were incubated with indicated primary antibody and immunoreactive dots were visualized; empty circles represent no immunoreactivity. One representative experiment out of 3 is shown. (B) mRNA (a, *n* = 8) and protein expression (b, one representative experiment out of 3 is shown) of HCN isoforms after S-LPS or R595 treatment (10 μg/mL, 6 h) in HL-1 cells using qPCR and Western blot, respectively.](gr4){#f0020}

![Effect of ivabradine on pacemaker current of human atrial myocytes.\
(A) Mean *I--V* relationships of *I*~f~ before and after ivabradine superfusion (1 μmol/L, 7 min). Inset shows the voltage clamp protocol. (B) *I*~f~ steady-state activation in control and ivabradine superfused cells. Normalized conductances were fitted by a Boltzmann function. Control: *V*~1/2~ = − 83.3 ± 1.2 mV, *k* = 7.8 ± 0.4 mV; ivabradine: *V*~1/2~ = − 84.1 ± 4.0 mV, *k* = 7.9 ± 2.5 mV. (C) Mean time constants of *I*~f~ activation before and after ivabradine superfusion. Values were obtained by fitting a monoexponential function to current traces. \**p* ≤ 0.05 vs. control.](gr5){#f0025}

![Effect of ivabradine on I~f~ characteristics in human atrial myocytes under septic conditions.\
Cells were incubated with endotoxins (10 μg/mL, 6--10 h) and superfused with ivabradine (1 μmol/L, 7 min). Mean *I--V* relationships of *I*~f~ in S-LPS (A) or R595 incubated cells (B) before and after ivabradine superfusion. (C) Use-dependent development of ivabradine blockage of *I*~f~. Currents were elicited by hyperpolarizing voltage steps to − 100 mV (3 s duration) at 1/6 Hz. (D). Percentage of *I*~f~ reduction by ivabradine was calculated from the underlying *I--V* relationships before and after ivabradine perfusion. ^‡^*p* ≤ 0.05 vs. S-LPS; ^§^*p* ≤ 0.05 vs. R595; \**p* ≤ 0.05 vs. control; ^\#^*p* ≤ 0.05 vs. ivabradine.](gr6){#f0030}

![Intracellular ivabradine concentrations in guinea pig ventricular myocytes under septic conditions.\
Untreated (controls) and endotoxin-treated (S-LPS or R595, 10 μg/mL, 6 h) cells were incubated with ivabradine (1 μmol/L, 15 min). (A) Representative HPLC-chromatograms for intracellular ivabradine content in control and S-LPS treated cells. (B) Percentage change of intracellular ivabradine concentrations in S-LPS and R595 incubated cells compared to respective controls. \**p* ≤ 0.05 vs. control.](gr7){#f0035}

![Effects of S-LPS and ivabradine on pacemaker activity of a sinoatrial cell model.\
A rabbit sinoatrial pacemaker cell model was used to investigate S-LPS-induced *V*~1/2~ shift of − 14 mV and ivabradine-induced *I*~f~ reduction (66% and 35% in control and S-LPS-treated cells, respectively). (A) *I--V* relationships of *I*~f~ using the computational model: *I*~f~ was voltage clamped from − 40 to − 140 mV in 10 mV steps of 3 s duration for indicated conditions (1) control, (2) ivabradine, (3) S-LPS, (4) S-LPS and ivabradine. (B) Time course of spontaneous action potentials computed for indicated conditions (1) to (4). (C) Changes in cycle length (CL) are represented as a function of (i) reduction in *I*~f~ conductance (*I*~f~ scaling factor) and (ii) *I*~f~--*V*~1/2~ shift to more negative membrane potentials. The arrows indicate the specific parameter setting (1) to (4).](gr8){#f0040}
